-
1
-
-
0029082109
-
Symptoms, signs, and diagnosis of schizophrenia
-
Andreasen N. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995; 346: 477-81.
-
(1995)
Lancet
, vol.346
, pp. 477-481
-
-
Andreasen, N.1
-
2
-
-
0031967082
-
Suicide in schizophrenia: Risk factors and clozapine treatment
-
Meltzer H. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998; 59(Suppl 3): 15-20.
-
(1998)
J Clin Psychiatry
, vol.59
, Issue.SUPPL. 3
, pp. 15-20
-
-
Meltzer, H.1
-
3
-
-
0032868798
-
The role of serotonin in antipsychotic drug action
-
Meltzer H. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21(2 Suppl): 106S-15S.
-
(1999)
Neuropsychopharmacology
, vol.21
, Issue.2 SUPPL.
-
-
Meltzer, H.1
-
4
-
-
33644875319
-
Occurrence and treatment of depressive comorbidity/ cosyndromality in schizophrenic psychoses: Conceptual and treatment issues
-
Möller H. Occurrence and treatment of depressive comorbidity/ cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World J Biol Psychiatry 2005; 6: 247-63.
-
(2005)
World J Biol Psychiatry
, vol.6
, pp. 247-263
-
-
Möller, H.1
-
5
-
-
0033850147
-
Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents
-
Siris SG. Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents. Am J Psychiatry 2000; 157: 1379-89.
-
(2000)
Am J Psychiatry
, vol.157
, pp. 1379-1389
-
-
Siris, S.G.1
-
7
-
-
23844434863
-
History of the discovery and clinical introduction of chlorpromazine
-
López-Muñoz F, Alamo C, Cuenca E, Shen W, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 2005; 17: 113-35.
-
(2005)
Ann Clin Psychiatry
, vol.17
, pp. 113-135
-
-
López-Muñoz, F.1
Alamo, C.2
Cuenca, E.3
Shen, W.4
Clervoy, P.5
Rubio, G.6
-
8
-
-
0017068246
-
Antipsychotic drug doses and neuroleptic/dopamine receptors
-
Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-9.
-
(1976)
Nature
, vol.261
, pp. 717-719
-
-
Seeman, P.1
Lee, T.2
Chau-Wong, M.3
Wong, K.4
-
9
-
-
0034608741
-
Schizophrenia: More dopamine, more D2 receptors
-
Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000; 97: 7673-5.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 7673-7675
-
-
Seeman, P.1
Kapur, S.2
-
10
-
-
0017585335
-
Dopaminergic factors in human prolactin regulation: Effects of neuroleptics and dopamine
-
Langer G, Sachar E. Dopaminergic factors in human prolactin regulation: effects of neuroleptics and dopamine. Psychoneuroendocrinology 1977; 2: 373-8.
-
(1977)
Psychoneuroendocrinology
, vol.2
, pp. 373-378
-
-
Langer, G.1
Sachar, E.2
-
11
-
-
0037215345
-
Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects
-
Halbreich U, Kinon B, Gilmore J, Kahn L. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28(Suppl 1): 53-67.
-
(2003)
Psychoneuroendocrinology
, vol.28
, Issue.SUPPL. 1
, pp. 53-67
-
-
Halbreich, U.1
Kinon, B.2
Gilmore, J.3
Kahn, L.4
-
12
-
-
0037377202
-
Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials
-
Kinon B, Gilmore J, Liu H, Halbreich U. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003; 28(Suppl 2): 69-82.
-
(2003)
Psychoneuroendocrinology
, vol.28
, Issue.SUPPL. 2
, pp. 69-82
-
-
Kinon, B.1
Gilmore, J.2
Liu, H.3
Halbreich, U.4
-
13
-
-
0033598803
-
Cognition, schizophrenia, and the atypical antipsychotic drugs
-
Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci USA 1999; 96: 13591-3.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 13591-13593
-
-
Meltzer, H.Y.1
Park, S.2
Kessler, R.3
-
15
-
-
0028114486
-
An overview of the mechanism of action of clozapine
-
Meltzer H. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55(Suppl B): 47-52.
-
(1994)
J Clin Psychiatry
, vol.55
, Issue.SUPPL. B
, pp. 47-52
-
-
Meltzer, H.1
-
16
-
-
0032751075
-
Antipsychotic-induced weight gain: A comprehensive research synthesis
-
Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
-
(1999)
Am J Psychiatry
, vol.156
, pp. 1686-1696
-
-
Allison, D.1
Mentore, J.2
Heo, M.3
Chandler, L.4
Cappelleri, J.5
Infante, M.6
-
17
-
-
0032734322
-
Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia
-
Kasper S, Hale A, Azorin J, Möller H. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 2): 1-14.
-
(1999)
Eur Arch Psychiatry Clin Neurosci
, vol.249
, Issue.SUPPL. 2
, pp. 1-14
-
-
Kasper, S.1
Hale, A.2
Azorin, J.3
Möller, H.4
-
18
-
-
33645464191
-
Weight change with atypical antipsychotics in the treatment of schizophrenia
-
Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005; 19(Suppl 6): 16-27.
-
(2005)
J Psychopharmacol
, vol.19
, Issue.SUPPL. 6
, pp. 16-27
-
-
Haddad, P.1
-
19
-
-
33746846535
-
Differential metabolic effects of antipsychotic treatments
-
Haupt D. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006; 16(Suppl 3): S149-55.
-
(2006)
Eur Neuropsychopharmacol
, vol.16
, Issue.SUPPL. 3
-
-
Haupt, D.1
-
20
-
-
53449092050
-
Serotonergic approaches in the development of novel antipsychotics
-
Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008; 55: 1056-65.
-
(2008)
Neuropharmacology
, vol.55
, pp. 1056-1065
-
-
Jones, C.A.1
McCreary, A.C.2
-
22
-
-
22344431960
-
Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: Affinity, efficacy and potential implications for treatment of schizophrenia
-
Newman-Tancredi A, Assié ML, N., Ormière A, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005; 8: 341-56.
-
(2005)
Int J Neuropsychopharmacol
, vol.8
, pp. 341-356
-
-
Newman-Tancredi, A.1
Assié2
ML, N.3
Ormière, A.4
Danty, N.5
Cosi, C.6
-
23
-
-
33645451501
-
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release
-
Cosi C, Carilla-Durand E, Assie MB, Ormiere AM, Maraval M, Leduc N, et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 2006; 535: 135-44.
-
(2006)
Eur J Pharmacol
, vol.535
, pp. 135-144
-
-
Cosi, C.1
Carilla-Durand, E.2
Assie, M.B.3
Ormiere, A.M.4
Maraval, M.5
Leduc, N.6
-
24
-
-
34247892865
-
F15063, a potential antipsychotic with D2//D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile
-
Newman-Tancredi A, Assie MB, Martel JC, Cosi C, Slot LB, Palmier C, et al. F15063, a potential antipsychotic with D2//D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile. Br J Pharmacol 2007; 151: 237-52.
-
(2007)
Br J Pharmacol
, vol.151
, pp. 237-252
-
-
Newman-Tancredi, A.1
Assie, M.B.2
Martel, J.C.3
Cosi, C.4
Slot, L.B.5
Palmier, C.6
-
25
-
-
0030063466
-
Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors
-
Newman-Tancredi A, Chaput C, Verriele L, Millan MJ. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 1996; 35: 119-21.
-
(1996)
Neuropharmacology
, vol.35
, pp. 119-121
-
-
Newman-Tancredi, A.1
Chaput, C.2
Verriele, L.3
Millan, M.J.4
-
26
-
-
34347336444
-
Neuropharmacological profile of bifeprunox: Merits and limitations in comparison with other third-generation antipsychotics
-
Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007; 8: 539-54.
-
(2007)
Curr Opin Investig Drugs
, vol.8
, pp. 539-554
-
-
Newman-Tancredi, A.1
Cussac, D.2
Depoortere, R.3
-
28
-
-
0032466835
-
S 16924 ((R)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)- ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol
-
Millan MJ, Schreiber R, Dekeyne A, Rivet J-M, Bervoets K, Mavridis M, et al. S 16924 ((R)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)- ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 1998; 286: 1356-73.
-
(1998)
J Pharmacol Exp Ther
, vol.286
, pp. 1356-1373
-
-
Millan, M.J.1
Schreiber, R.2
Dekeyne, A.3
Rivet, J.-M.4
Bervoets, K.5
Mavridis, M.6
-
29
-
-
0026667827
-
Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue
-
Mason S, Reynolds G. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol 1992; 221: 397-8.
-
(1992)
Eur J Pharmacol
, vol.221
, pp. 397-398
-
-
Mason, S.1
Reynolds, G.2
-
30
-
-
0036089687
-
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
-
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-9.
-
(2002)
J Pharmacol Exp Ther
, vol.302
, pp. 381-389
-
-
Burris, K.D.1
Molski, T.F.2
Xu, C.3
Ryan, E.4
Tottori, K.5
Kikuchi, T.6
-
31
-
-
20344400385
-
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic
-
Tadori Y, Miwa T, Tottori K, Burris K, Stark A, Mori T, et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 2005; 515: 10-9.
-
(2005)
Eur J Pharmacol
, vol.515
, pp. 10-19
-
-
Tadori, Y.1
Miwa, T.2
Tottori, K.3
Burris, K.4
Stark, A.5
Mori, T.6
-
33
-
-
0042887023
-
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology
-
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L-X, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-11.
-
(2003)
Neuropsychopharmacology
, vol.28
, pp. 1400-1411
-
-
Shapiro, D.A.1
Renock, S.2
Arrington, E.3
Chiodo, L.A.4
Liu, L.-X.5
Sibley, D.R.6
-
34
-
-
0026098660
-
Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia
-
Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991; 48: 355-63.
-
(1991)
Life Sci
, vol.48
, pp. 355-363
-
-
Hashimoto, T.1
Nishino, N.2
Nakai, H.3
Tanaka, C.4
-
35
-
-
0030273870
-
5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia
-
Burnet P, Eastwood S, Harrison P. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996; 15: 442-55.
-
(1996)
Neuropsychopharmacology
, vol.15
, pp. 442-455
-
-
Burnet, P.1
Eastwood, S.2
Harrison, P.3
-
36
-
-
0036270010
-
Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635
-
Tauscher J, Kapur S, Verhoeff NPLG, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, et al. Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 2002; 59: 514-20.
-
(2002)
Arch Gen Psychiatry
, vol.59
, pp. 514-520
-
-
Tauscher, J.1
Kapur, S.2
Verhoeff, N.P.L.G.3
Hussey, D.F.4
Daskalakis, Z.J.5
Tauscher-Wisniewski, S.6
-
37
-
-
1542408468
-
Decreased 5-HT1A receptor binding in amygdala of schizophrenia
-
Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 2004; 55: 439-44.
-
(2004)
Biol Psychiatry
, vol.55
, pp. 439-444
-
-
Yasuno, F.1
Suhara, T.2
Ichimiya, T.3
Takano, A.4
Ando, T.5
Okubo, Y.6
-
38
-
-
0029670799
-
Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia
-
Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 1996; 708: 209-14.
-
(1996)
Brain Res
, vol.708
, pp. 209-214
-
-
Sumiyoshi, T.1
Stockmeier, C.A.2
Overholser, J.C.3
Dilley, G.E.4
Meltzer, H.Y.5
-
39
-
-
0033696731
-
Improving the treatment of schizophrenia: Focus on serotonin (5-HT)1A receptors
-
Millan MJ. Improving the treatment of schizophrenia: Focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 2000; 295: 853-61.
-
(2000)
J Pharmacol Exp Ther
, vol.295
, pp. 853-861
-
-
Millan, M.J.1
-
40
-
-
0034745153
-
1A receptor in schizophrenia: A promising target for novel atypical neuroleptics?
-
1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001; 15: 37-46.
-
(2001)
J Psychopharmacol
, vol.15
, pp. 37-46
-
-
Bantick, R.A.1
Deakin, J.F.W.2
Grasby, P.3
-
41
-
-
52949136219
-
Learning and memory in 5-HT-1A mutant mice
-
Bert B, Fink H, Rothe J, Walstab J, Bonisch H. Learning and memory in 5-HT-1A mutant mice. Behav Brain Res 2008; 195: 78-85.
-
(2008)
Behav Brain Res
, vol.195
, pp. 78-85
-
-
Bert, B.1
Fink, H.2
Rothe, J.3
Walstab, J.4
Bonisch, H.5
-
43
-
-
18544372627
-
Beyond hypofrontality: A quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia
-
Glahn D, Ragland J, Abramoff A, Barrett J, Laird A, Bearden C, et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp 2005; 25: 60-9.
-
(2005)
Hum Brain Mapp
, vol.25
, pp. 60-69
-
-
Glahn, D.1
Ragland, J.2
Abramoff, A.3
Barrett, J.4
Laird, A.5
Bearden, C.6
-
44
-
-
77956751404
-
The cortical dopamine system: Role in memory and cognition
-
Goldman-Rakic P. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 1998; 42: 707-11.
-
(1998)
Adv Pharmacol
, vol.42
, pp. 707-711
-
-
Goldman-Rakic, P.1
-
45
-
-
0029149615
-
Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for common ground
-
Weinberger D, Lipska B. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 1995; 16: 87-110.
-
(1995)
Schizophr Res
, vol.16
, pp. 87-110
-
-
Weinberger, D.1
Lipska, B.2
-
46
-
-
0037036059
-
5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex
-
Ichikawa J, Dai J, Meltzer H. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 2002; 939: 34-42.
-
(2002)
Brain Res
, vol.939
, pp. 34-42
-
-
Ichikawa, J.1
Dai, J.2
Meltzer, H.3
-
47
-
-
0036176263
-
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum
-
Ichikawa J, Dai J, O'Laughlin I, Fowler W, Meltzer H. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002; 26: 325-39.
-
(2002)
Neuropsychopharmacology
, vol.26
, pp. 325-339
-
-
Ichikawa, J.1
Dai, J.2
O'Laughlin, I.3
Fowler, W.4
Meltzer, H.5
-
49
-
-
2942551105
-
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain
-
Li Z, Ichikawa J, Dai J, Meltzer H. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004; 493: 75-83.
-
(2004)
Eur J Pharmacol
, vol.493
, pp. 75-83
-
-
Li, Z.1
Ichikawa, J.2
Dai, J.3
Meltzer, H.4
-
50
-
-
0027183471
-
The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux
-
Pehek E, Meltzer H, Yamamoto B. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol 1993; 240: 107-9.
-
(1993)
Eur J Pharmacol
, vol.240
, pp. 107-109
-
-
Pehek, E.1
Meltzer, H.2
Yamamoto, B.3
-
51
-
-
0028242723
-
Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex
-
Nomikos G, Iurlo M, Andersson J, Kimura K, Svensson T. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 1994; 115: 147-56.
-
(1994)
Psychopharmacology (Berl)
, vol.115
, pp. 147-156
-
-
Nomikos, G.1
Iurlo, M.2
Andersson, J.3
Kimura, K.4
Svensson, T.5
-
52
-
-
0030694503
-
Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation
-
Rollema H, Lu Y, Schmidt A, Zorn S. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 1997; 338: R3-5.
-
(1997)
Eur J Pharmacol
, vol.338
-
-
Rollema, H.1
Lu, Y.2
Schmidt, A.3
Zorn, S.4
-
55
-
-
0034608753
-
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
-
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-9.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 8104-8109
-
-
Abi-Dargham, A.1
Rodenhiser, J.2
Printz, D.3
Zea-Ponce, Y.4
Gil, R.5
Kegeles, L.S.6
-
56
-
-
0029787944
-
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
-
Laruelle M, Abi-Dargham A, van Dyc CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-40.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 9235-9240
-
-
Laruelle, M.1
Abi-Dargham, A.2
van Dyc, C.H.3
Gil, R.4
D'Souza, C.D.5
Erdos, J.6
-
57
-
-
0024247522
-
The current staus of the the dopamine hypothesis of schizophrenia
-
Carlsson A. The current staus of the the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-86.
-
(1988)
Neuropsychopharmacology
, vol.1
, pp. 179-186
-
-
Carlsson, A.1
-
59
-
-
33645419546
-
The acute and chronic administration of (±)-8-hydroxy-2-(di-n-propylamino) tetralin significantly alters the activity of spontaneously active midbrain dopamine neurons in rats: An in vivo electrophysiological study
-
Nakamura K, Suzuki K, McCreary A, Ashby CJ. The acute and chronic administration of (±)-8-hydroxy-2-(di-n-propylamino) tetralin significantly alters the activity of spontaneously active midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 2006; 59: 359-67.
-
(2006)
Synapse
, vol.59
, pp. 359-367
-
-
Nakamura, K.1
Suzuki, K.2
McCreary, A.3
Ashby, C.J.4
-
60
-
-
0031815815
-
Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535
-
Lejeune F, Millan MJ. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 1998; 30: 172-80.
-
(1998)
Synapse
, vol.30
, pp. 172-180
-
-
Lejeune, F.1
Millan, M.J.2
-
61
-
-
0027336182
-
The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons
-
Arborelius L, Chergui K, Murase S, Nomikos G, Höök B, Chouvet G, et al. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedebergs Arch Pharmacol 1993; 347: 353-62.
-
(1993)
Naunyn-Schmiedebergs Arch Pharmacol
, vol.347
, pp. 353-362
-
-
Arborelius, L.1
Chergui, K.2
Murase, S.3
Nomikos, G.4
Höök, B.5
Chouvet, G.6
-
62
-
-
4544371130
-
Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex
-
Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2004; 14: 1100-9.
-
(2004)
Cereb Cortex
, vol.14
, pp. 1100-1109
-
-
Santana, N.1
Bortolozzi, A.2
Serrats, J.3
Mengod, G.4
Artigas, F.5
-
63
-
-
0034810016
-
Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
-
Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001; 158: 1722-5.
-
(2001)
Am J Psychiatry
, vol.158
, pp. 1722-1725
-
-
Sumiyoshi, T.1
Matsui, M.2
Nohara, S.3
Yamashita, I.4
Kurachi, M.5
Sumiyoshi, C.6
-
64
-
-
0035873389
-
The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia
-
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry 2001; 49: 861-8.
-
(2001)
Biol Psychiatry
, vol.49
, pp. 861-868
-
-
Sumiyoshi, T.1
Matsui, M.2
Yamashita, I.3
Nohara, S.4
Kurachi, M.5
Uehara, T.6
-
65
-
-
0034030291
-
Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia
-
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 2000; 20: 386-8.
-
(2000)
J Clin Psychopharmacol
, vol.20
, pp. 386-388
-
-
Sumiyoshi, T.1
Matsui, M.2
Yamashita, I.3
Nohara, S.4
Uehara, T.5
Kurachi, M.6
-
66
-
-
34548189417
-
Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study
-
Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer H. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res 2007; 95: 158-68.
-
(2007)
Schizophr Res
, vol.95
, pp. 158-168
-
-
Sumiyoshi, T.1
Park, S.2
Jayathilake, K.3
Roy, A.4
Ertugrul, A.5
Meltzer, H.6
-
67
-
-
0025869319
-
An open trial of buspirone added to neuroleptics in schizophrenic patients
-
Goff D, Midha K, Brotman A, McCormick S, Waites M, Amico E. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 193-7.
-
(1991)
J Clin Psychopharmacol
, vol.11
, pp. 193-197
-
-
Goff, D.1
Midha, K.2
Brotman, A.3
McCormick, S.4
Waites, M.5
Amico, E.6
-
68
-
-
0034919110
-
An open study of buspirone augmentation of neuroleptics in patients with schizophrenia
-
Sirota P, Epstein B, Benatov R, Sousnostzky M, Kindler S. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psychopharmacol 2001; 21: 454-5.
-
(2001)
J Clin Psychopharmacol
, vol.21
, pp. 454-455
-
-
Sirota, P.1
Epstein, B.2
Benatov, R.3
Sousnostzky, M.4
Kindler, S.5
-
74
-
-
0037498629
-
Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats
-
Winstanley C, Chudasama Y, Dalley J, Theobald D, Glennon J, Robbins T. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl) 2003; 167: 304-14.
-
(2003)
Psychopharmacology (Berl)
, vol.167
, pp. 304-314
-
-
Winstanley, C.1
Chudasama, Y.2
Dalley, J.3
Theobald, D.4
Glennon, J.5
Robbins, T.6
-
78
-
-
21644447088
-
Novel antipsychotic agents with 5-HT(1A) agonist properties: Role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats
-
Kleven M, Barret-Grévoz C, Bruins Slot L, Newman-Tancredi A. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 2005; 49: 135-43.
-
(2005)
Neuropharmacology
, vol.49
, pp. 135-143
-
-
Kleven, M.1
Barret-Grévoz, C.2
Bruins Slot, L.3
Newman-Tancredi, A.4
-
79
-
-
34250166183
-
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats
-
Auclair A, Galinier A, Besnard J, Newman-Tancredi A, Depoortère R. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology 2007; 193: 45-54.
-
(2007)
Psychopharmacology
, vol.193
, pp. 45-54
-
-
Auclair, A.1
Galinier, A.2
Besnard, J.3
Newman-Tancredi, A.4
Depoortère, R.5
-
82
-
-
0342288642
-
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia
-
Keck PJ, Strakowski S, McElroy S. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61(Suppl 3): 4-9.
-
(2000)
J Clin Psychiatry
, vol.61
, Issue.SUPPL. 3
, pp. 4-9
-
-
Keck, P.J.1
Strakowski, S.2
McElroy, S.3
-
83
-
-
0037304917
-
1A agonists in the treatment of depression?
-
1A agonists in the treatment of depression? Biol Psychiatry 2003; 53: 193-203.
-
(2003)
Biol Psychiatry
, vol.53
, pp. 193-203
-
-
Blier, P.1
Ward, N.M.2
-
84
-
-
0027277135
-
1A receptor ligands in animal models of anxiety, impulsivity and depression: Multiple mechanisms of action?
-
1A receptor ligands in animal models of anxiety, impulsivity and depression: Multiple mechanisms of action? Progr Neuro-Psychopharmacol Biol Psychiatry 1993; 17: 87-104.
-
(1993)
Progr Neuro-Psychopharmacol Biol Psychiatry
, vol.17
, pp. 87-104
-
-
Schreiber, R.1
De Vry, J.2
-
86
-
-
0027275084
-
Depression, demoralization and control over psychotic illness: A comparison of depressed and non-depressed patients with a chronic psychosis
-
Birchwood M, Mason R, MacMillan F, Healy J. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993; 23: 387-95.
-
(1993)
Psychol Med
, vol.23
, pp. 387-395
-
-
Birchwood, M.1
Mason, R.2
MacMillan, F.3
Healy, J.4
-
87
-
-
21644449358
-
SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actions
-
McCreary AC, Glennon J, Tuinstra T, Herremans AHJ, Van der Heyden JAM, Feenstra R, et al. SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actions. Eur Neuropsychopharmacol 2002; 12(Suppl 3): 274.
-
(2002)
Eur Neuropsychopharmacol
, vol.12
, Issue.SUPPL. 3
, pp. 274
-
-
McCreary, A.C.1
Glennon, J.2
Tuinstra, T.3
Herremans, A.H.J.4
Van der Heyden, J.A.M.5
Feenstra, R.6
-
88
-
-
47349107934
-
Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment
-
Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des 2008; 14(13): 1274-94.
-
(2008)
Curr Pharm Des
, vol.14
, Issue.13
, pp. 1274-1294
-
-
Gur, A.1
Oktayoglu, P.2
-
89
-
-
47349097789
-
Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach
-
Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 2008; 14(13): 1261-9.
-
(2008)
Curr Pharm Des
, vol.14
, Issue.13
, pp. 1261-1269
-
-
Sanna, G.1
Bertolaccini, M.L.2
Khamashta, M.A.3
-
90
-
-
55049138638
-
Pharmacological interventions for clozapine-induced hypersalivation
-
CD005579
-
Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, et al. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev 2008; (3): CD005579.
-
Cochrane Database Syst Rev
, vol.2008
, Issue.3
-
-
Syed, R.1
Au, K.2
Cahill, C.3
Duggan, L.4
He, Y.5
Udu, V.6
|